Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-447-3 | CAS number: 99607-70-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 October 1987 to 16 November 1987
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, guideline study, available as unpublished report, no restrictions, fully adequate for assessment
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- yes
- Remarks:
- occlusive dressing used
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-2 (Repeated Dose Dermal Toxicity -21/28 Days)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- EC Number:
- 619-447-3
- Cas Number:
- 99607-70-2
- Molecular formula:
- C18H22ClNO3
- IUPAC Name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- Details on test material:
- - Name of test material (as cited in study report): CGA185072 (company code)
- Analytical purity: 91.6%
- Physical state: solid
- Date of reanalysis: November 1990
- Storage condition of test material: room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Tif: RAIf rat, Sprague-Dawley derived
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source of animals: Ciba-Geigy Ltd., Animal Production, Sisseln, Switzerland
- Age at study initiation: 8 weeks
- Weight at study initiation (week -1): 261-323 g (males), 225-286 g (females)
- Fasting period before study: no
- Housing: individually in macrolon type 3 cages
- Diet: Nafag No. 890 Tox diet ad libitum
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22±3°C
- Humidity: 55±15%
- Air changes (per hr): approximately 15/hr
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: From:19.10.1987 To: 16.11.1987
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: shaved dorsum
- % coverage: 10% body surface
- Type of wrap if used: gauze pad backed with aluminium foil secured around trunk with adhesive tape
- Time intervals for shavings or clipplings: clipped 24 h prior to administration and at weekly intervals during the test
REMOVAL OF TEST SUBSTANCE
- Washing (if done): cleaned with lukewarm water
- Time after start of exposure: exposure was for 6h per day for 5 days per week for 4 weeks
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0, 50, 200 or 1000 mg/kg bw/day
- Concentration (if solution): test material applied as supplied
- test site and gauze pad moistened with distilled water immediately before application
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 6 hours per day
- Frequency of treatment:
- 5 days per week for 4 consecutive weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 50, 200 and 1000 mg/kg bw/day
Basis:
nominal per unit body weight
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, sham-exposed
- Details on study design:
- - Dose selection rationale: based on the findings of previous studies
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily for mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations: daily, approximately 17 hours after removal of the dressing
BODY WEIGHT: Yes
- Time schedule for examinations: pre-test and subsequently at weekly intervals
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks of treatment
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes, overnight
- How many animals: all survivors
- Parameters examined: erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, leucocyte count, differential leucocyte count, thrombocyte count, prothrombin time, red cell morphology
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after 4 weeks of treatment
- Animals fasted: Yes, overnight
- How many animals: all survivors
- Parameters examined: glucose, urea, total protein, albumin, globulins, A/G ratio, sodium, potassium, calcium, inorganic phosphorus, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (all animals)
- the following organs were weighed: brain, heart, liver, kidneys, adrenals, thymus, ovaries/testes, spleen .
HISTOPATHOLOGY: Yes (all animals)
- the following tissues were examined microscopically: skin (treated and untreated area), mammary area, spleen, mesenteric lymph node, axillary lymph node, popliteal lymph node, sternum with bone marrow, femur with joint, skeletal muscle, trachea, lung, heart, aorta, submandibular salivary gland, liver, pancreas, oesophagus, stomach, small intestine, large intestine, kidneys, urinary bladder, prostate, seminal vesicle, testis, epididymis, uterus, ovary, pituitary gland, adrenal gland, thyroid with parathyroid gland, thymus, peripheral nerve, brain, spinal cord, eye with optic nerve, extraorbital lacrimal gland, any tissue with gross lesions - Statistics:
- Univariate standard methods were applied
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Sex:
- male/female
- Basis for effect level:
- other: No systemic or local effects at highest dose tested.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Dermal administration of cloquintocet-mexyl was tolerated without any local or systemic effects at a limit dose of 1000 mg/kg bw/day. The NOAEL for systemic and local effects was 1000 mg/kg bw/day in this study
- Executive summary:
Five male and 5 female Tif:RAIf (SPF) rats were subject to topical application of cloquintocet-mexyl at dose levels of 0 (control), 50, 200 or 1000 mg/kg bw/day for 6 hours per day, five days per week for four consecutive weeks. Mortality, clinical appearance and behaviour, signs of skin irritation, bodyweights, bodyweight changes, food consumption, haematology, blood biochemistry, organ weights, gross pathology and histopathology were assessed.
Dermal administration of cloquintocet-mexyl was tolerated without any local or systemic effects at a limit dose of 1000 mg/kg bw/day. The NOAEL for systemic and local effects was 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.